Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEBULA-2 phase 3 study of efimosfermin alfa in adults with compensated cirrhosis due to MASH
CTR20263653Phase 3Active
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis comparing Efimosfermin alfa with Placebo (2 arms). Primary endpoint: Proportion of participants with at least 1-stage improvement in liver fibrosis and no worsening of MASH. Started Oct 2026; status: active.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on CTR20263653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263653.